5Y Capital, previously known as Morningside Venture Capital, is a private equity and venture capital firm based in Shanghai, China, with additional offices in Beijing and Hong Kong. Founded in 1992, it specializes in early-stage investments across a wide range of sectors, including healthcare, technology, fintech, consumer services, media, and education. The firm manages approximately USD 3 billion in funds, leveraging investments from prominent sovereign wealth funds, family offices, and other institutional investors. With an initial investment threshold of over USD 500,000 per portfolio company, 5Y Capital focuses primarily on opportunities in China and other emerging markets in Asia and the Pacific. It is a subsidiary of the Morningside Group, which has a long-standing commitment to socially responsible investing and philanthropic initiatives, particularly in education and scientific research.

Ben Franklin Technology Partners of Southeastern Pennsylvania is a non-profit organization established in 1982 that promotes the development and adoption of new technologies in the region. Over the past 30 years, it has emerged as a prominent provider of seed stage capital, investing more than $170 million in over 1,750 technology companies, many of which have achieved significant industry success. In addition to financial support, Ben Franklin fosters university and industry collaborations to expedite the commercialization of scientific innovations. The organization is dedicated to enhancing the regional entrepreneurial ecosystem, creating jobs, and transforming lives through its initiatives.

Wellington Management is a leading investment adviser founded in 1928, based in Boston, Massachusetts, with additional offices in major global financial centers. The firm specializes in providing comprehensive investment management solutions for a diverse range of institutional clients, including sovereign institutions, endowments, foundations, family offices, insurers, and wealth managers across more than 50 countries. Wellington Management employs a collaborative and research-driven approach, harnessing proprietary research to identify opportunities and manage risks in global equity, fixed income, alternatives, and multi-asset markets. The firm's structure fosters independent thought and enables teams to operate as entrepreneurial entities, ensuring they have the necessary resources to achieve strong, consistent results. Wellington Management also recognizes the importance of collaborating with consultants to address client needs effectively. Their commitment to environmental, social, and corporate governance (ESG) principles further enhances their investment strategies, reflecting a modern understanding of responsible investing.

Versant Ventures is a prominent healthcare investment firm founded in 1999 and headquartered in California. The firm specializes in investing across the healthcare sector, focusing on medical devices, biotechnology, and pharmaceuticals at various stages of company development. With $2.3 billion under management and offices in Canada, the U.S., and Europe, Versant Ventures emphasizes the discovery and development of novel therapeutics. The firm has cultivated a team with extensive investment, operational, and scientific expertise, allowing for a hands-on approach to building companies. Since its inception, more than 65 companies backed by Versant have successfully achieved acquisitions or initial public offerings.

OrbiMed is a healthcare-focused investment firm with approximately $5 billion in assets under management. Founded in 1989, the firm aims to invest across a diverse range of healthcare companies, from private startups to large multinational corporations. OrbiMed manages various investment vehicles, including venture capital funds under the Caduceus Private Investments series, as well as public equity funds. The firm specializes in a broad array of sectors within the healthcare industry, such as pharmaceuticals, biotechnology, medical devices, and healthcare services. With a global investment strategy, OrbiMed seeks to make significant investments, typically ranging from $3 million to $150 million, with a preference for taking majority stakes in its portfolio companies. The firm operates offices in major financial centers, including New York, San Francisco, Mumbai, Herzliya, Shanghai, and Luxembourg.

Aisling Capital, founded in 2000 and based in New York, is a private equity firm focused on mid-market and growth-oriented investments in the life sciences, healthcare, and technology sectors across the United States and Western Europe. The firm is positioned to capitalize on the anticipated revolution in healthcare driven by biotechnology, which is expected to transform the diagnosis, prevention, and treatment of serious illnesses. With the completion of the human genome project, new insights into the causes of disease have emerged, fostering innovative therapeutic approaches. Aisling Capital aims to support leading global healthcare companies in their efforts to develop and commercialize new therapeutics, addressing the growing demand for capital in this rapidly advancing field.

Lilly Asia Ventures is the venture capital arm of Eli Lilly and Company, focusing on investments in the life sciences and healthcare sectors across Asia, particularly in China. Founded in 2008, the firm targets promising companies that demonstrate strong management teams and innovative technologies or business models. Lilly Asia Ventures typically invests between $5 million and $15 million per funding round, aiming for a minority stake, usually less than 20 percent, in its portfolio companies. In addition to biopharmaceuticals and biotechnology, the firm also explores opportunities in medical technology, healthcare services, and broader life sciences, including agricultural biotechnology and nutraceuticals. While the primary focus is on China, the firm is open to investment opportunities in other East and South Asian markets.

RA Capital Management is an investment advisor located in Boston that focuses on the life sciences and drug development sectors. Established in 2001, the firm has a team of professionals with expertise in biology, chemistry, and medicine, complemented by experience in industry and business development at executive and board levels. RA Capital invests in both public and private healthcare companies, targeting those with innovative technologies and products, from seed funding to later-stage financing. Their investment strategy emphasizes a deep understanding of data, trial design, regulatory processes, and commercial viability. The firm also provides its portfolio companies with opportunities for in-licensing and strategic partnerships, along with insights into public market demands. RA Capital typically participates in early and multi-stage investments, aiming to support advancements in areas such as diagnostics, personalized medicine, and cost-effective healthcare solutions.

Novo Holdings, established in 1999, serves as the holding company for the Novo Group and oversees the investment assets of the Novo Nordisk Foundation. It primarily focuses on two investment categories: Life Science Investments, which targets life science companies at all stages of development, and Financial Investments, which manages a diverse portfolio of equity and fixed income securities. Operating from offices in Copenhagen, San Francisco, and Boston, Novo Holdings is recognized as a prominent life science investor committed to generating long-term value. The organization aims to grow the Foundation's assets and provide returns that support scientific, social, and humanitarian initiatives, enhancing global health and welfare. Additionally, Novo Holdings maintains a significant influence in the Novo Group companies, ensuring they align with the Foundation's values and objectives. The company has also launched initiatives like Novo Seeds to support early-stage applied research in Scandinavia and invests in promising later-stage life science companies.

IP Group, established in 2001 and based in London, focuses on creating value through the commercialization of intellectual property from research-intensive institutions. The firm excels in identifying suitable intellectual property for commercialization and is adept at developing businesses or forming strategic partnerships to maximize value. With a strong foundation of industry and financial expertise, IP Group has built a solid reputation for delivering consistent results for its companies, partners, and shareholders. By leveraging its extensive knowledge of the commercialization process, IP Group effectively bridges the gap between innovative research and market application, fostering growth and sustainability in its business endeavors.